Adjuvant Chemotherapy With FOLFOX After Total Mesorectal Excision for Locally Advanced Rectal Cancer; an Open-label, Multicenter, Prospective, Randomized Phase 3 Trial
试验速览
- 阶段
- 2 期
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Disease free survival (DFS)
研究概览
简要总结
The introduction of total mesorectal excision (TME) and the progress of neoadjuvant chemoradiotherapy has significantly reduced the risk of local recurrence in locally advanced rectal cancer. However, systemic recurrence rate is not being improved and that is considered as the cause of unsatisfactory overall survival of patients with rectal cancer. Relatively higher systemic relapse rate than local recurrence rate is probably due to the insufficient control of systemic micrometastasis during adjuvant chemotherapy. The efficacy of adjuvant combination cytotoxic chemotherapy after surgery in treatment of rectal cancer remains controversial. In addition, preoperative radiotherapy increases surgical complication such as anastomosis site leakage and radiotherapy itself worsen sexual and urinary function and bowel habit which result in aggravation of the quality of life. Furthermore the preoperative chemoradiotherapy upto 3 months not only extends treatment period but increases cost of care. To reduce the possibility of overtreatment, it is needed to confirm that the preoperative chemoradiotherapy is absolutely necessary to locally advanced rectal cancer patients with safe circumferential margin (CRM) resected curatively by standardized TME operation.
In this study, investigators aim to evaluate the efficacy of adjuvant FOLFOX chemotherapy after TME without preoperative chemoradiotherapy in patients with locally advanced rectal cancer having spared CRM are not inferior to that of current standard treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the rectum below 10 cm from the anal verge
- •Locally advanced rectal cancer (T3N0 or T1-3N+)
- •Age: 19-80 years old.
- •Without evidence of distant metastasis including paraortic lymph node, common & external iliac lymph node metastasis
- •MRI scan confirmed more than 2 mm circumferential margin
- •ECOG(Eastern Cooperative Oncology Group) performance status 0-2
- •preoperative ASA class I-III
- •No prior systemic treatment for rectal cancer (i.e. chemotherapy or immunotherapy)
- •No history of regional radiation treatment in the pelvic cavity
- •Adequate hematologic function: ANC(absolute neutrophil count) ≥ 1.5×109/L，Platelet ≥ 100×109/L, Adequate renal function: Cr ≤ 1.5×ULN or Glomerular filtration rate (Ccr calculated by Cockcroft formula) ≥ 50 ml/min, Adequate hepatic function: ALT(Alanine aminotransferase)/AST(aspartate aminotransferase) ≤ 2.5×ULN, Total bilirubin ≤ 1.5×ULN
- •Patients must be willing and able to comply with the protocol duration of the study
- •Signed informed consent
排除标准
- •Malignancy of the rectum other than adenocarcinoma or adenocarcinoma developed from inflammatory bowel disease
- •Suspicious distant metastasis
- •Patients with peripheral neuropathy ≥ NCI CTC(common terminology criteria) grade 1
- •Uncontrolled and significant cardiovascular disease (i.e. NYHA(New York Heart Association) class III or IV heart failure, myocardial infarction within the past 6 months, uncontrolled angina pectoris)
- •Uncontrolled active infection or serious concomitant systemic disorders incompatible with the study
- •Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin
- •Patients requiring immunosuppressive treatment who received organ transplantation
- •Uncontrolled epilepsy and psychiatric disease
- •Pregnant or lactating patient
- •Females with a positive or no pregnancy test unless childbearing potential can be otherwise excluded (amenorrheic for at least 2 years,hysterectomy or oophorectomy)
- •Patients receiving a concomitant treatment with drugs interacting with 5-Fluorouracil or oxaliplatin such as flucytosine, phenytoin, or warfarin
- •Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-Fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •Known hypersensitivity to platinum-based drugs, leucovorin or capecitabine
- •Patients taking sorivudine or brivudine
- •Patients taking tegafur, gimeracil, oteracil potassium complex or stopped the medication within 7days before.
- •Patients who have hereditary disease like as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.
- •Participant in any clinical trial within 4 weeks before initiation of the study
- •Treatment with bevacizumab, cetuximab, oxaliplatin or irinotecan before screening
结局指标
主要结局
Disease free survival (DFS)
时间窗: 3 years
次要结局
- Overall survival (OS)(3 years and 5 years)
- Systemic recurrence rate(3 years and 5 years)
- Total score for function of urination (IPSS) and defecation (Wexner's score)(1 month and 6 months after surgery)
- Evaluation for rate of various events after surgery(14 days after surgery)
- Disease free survival (DFS)(5 years)
- Local recurrence rate(3 years and 5 years)